FDA approves perioperative Imfinzi plus enfortumab vedotin regimen for cisplatin‑ineligible bladder cancer
+2 new sources since this summary was written
The U.S. Food and Drug Administration granted approval for AstraZeneca's Imfinzi (durvalumab) combined with enfortumab vedotin as a neoadjuvant treatment, followed by Imfinzi monotherapy after radical cystectomy, for adults with muscle‑invasive bladder cancer who cannot receive cisplatin. The decision is based on the Phase III VOLGA trial, which showed a 49 % lower chance of disease progression, recurrence, failure to undergo surgery or death, and a 42 % lower chance of death compared with surgery alone. The regimen will be available to an estimated 16,000 U.S. patients in 2026, roughly half of whom are ineligible for cisplatin‑based therapy.
Why it matters
The approval adds a new perioperative immunotherapy option for a large, underserved patient group, potentially expanding AstraZeneca's bladder‑cancer franchise and driving future sales. The FDA’s priority‑review status and the trial’s survival benefits suggest the regimen could become a new standard of care for cisplatin‑ineligible patients.
Key facts
- 1The FDA approved the Imfinzi plus enfortumab vedotin regimen for adults with muscle‑invasive bladder cancer who are ineligible for or have refused cisplatin‑based chemotherapy. astrazeneca.com
- 2The regimen consists of three cycles of Imfinzi and enfortumab vedotin before radical cystectomy, followed by nine cycles of adjuvant Imfinzi monotherapy. securities.io
- 3In the VOLGA Phase III trial, the combination reduced the risk of disease progression, recurrence, failure to undergo surgery or death by 49 % versus the comparator. securities.io
- 4The same trial showed a 42 % reduction in the risk of death for the combination arm. astrazeneca.com
- 5Estimated two‑year event‑free survival was 64 % for the combination versus 45 % for the comparator. astrazeneca.com
- 6AstraZeneca estimates that about 16,000 patients will be treated for muscle‑invasive bladder cancer in the United States in 2026, and up to 50 % are ineligible for cisplatin. securities.io
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.